Lantheus price target raised to $98 from $89 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Lantheus (LNTH) to $98 from $89 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that the stock’s current multiple is too dislocated and certainly does not reflect the double-digit revenue and EPS growth prospects for the company in 2027 and beyond.